Skip to main content

Table 1 Patient baseline demographic and clinical characteristics

From: A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US

  Total First LOT
GEM + DOC DOX PAZO DOX + IFO GEM Others Overall p value
N (%) 555 (100) 124 (22.3) 72 (13.0) 38 (6.8) 31 (5.6) 29 (5.2) 261 (47.0)  
Age, mean (95% CI) 58.8 (57.5–60.2) 57.1 (54.9–59.3) 65.9 (62.5–69.3) 59.0 (53.3–64.7) 54.7 (48.9–60.4) 66.3 (61.5–71.1) 57.4 (55.2–59.5) < 0.001
Age categories, n (%)
 18–44 108 (19.5) 17 (13.7) 6 (8.3) 11 (29.0) 10 (32.3) 1 (3.5) 63 (24.1) < 0.001
 45–54 91 (16.4) 30 (24.2) 9 (12.5) 3 (7.9) 3 (9.7) 4 (13.8) 42 (16.1) 0.091
 55–64 132 (23.8) 42 (33.9) 16 (22.2) 8 (21.1) 7 (22.6) 6 (20.7) 53 (20.3) 0.104
 65–74 128 (23.1) 28 (22.6) 19 (26.4) 8 (21.1) 10 (32.3) 8 (27.6) 55 (21.1) 0.708
 75+ 96 (17.3) 7 (5.7) 22 (30.6) 8 (21.1) 1 (3.2) 10 (34.5) 48 (18.4) < 0.001
Female, n (%) 257 (46.3) 75 (60.5) 36 (50.0) 21 (55.3) 10 (32.3) 13 (44.8) 102 (39.1) 0.001
Coverage type, n (%)
 Commercial 363 (65.4) 90 (72.6) 38 (52.8) 28 (73.7) 22 (71.0) 15 (51.7) 170 (65.1) 0.036
  Aged < 65 years 318 (87.6) 85 (94.4) 30 (79.0) 22 (78.6) 20 (90.9) 10 (66.7) 151 (88.8) 0.010
  Aged 65+ years 45 (12.4) 5 (5.6) 8 (21.1) 6 (21.4) 2 (9.1) 5 (33.3) 19 (11.1) 0.010
 Medicare advantage 192 (34.6) 34 (27.4) 34 (47.2) 10 (26.3) 9 (29.0) 14 (48.3) 91 (34.9) 0.036
Geographic region, n (%)
 Northeast 92 (16.6) 17 (13.7) 11 (15.3) 7 (18.4) 8 (25.8) 6 (20.7) 43 (16.5) 0.672
 Midwest 151 (27.2) 32 (25.8) 24 (33.3) 10 (26.3) 8 (25.8) 9 (31.0) 68 (26.1) 0.860
 South 228 (41.1) 57 (46.0) 25 (34.7) 17 (44.7) 9 (29.0) 9 (31.0) 111 (42.5) 0.313
 West 84 (15.1) 18 (14.5) 12 (16.7) 4 (10.5) 6 (19.4) 5 (17.2) 39 (14.9) 0.931
Quan-Charlson comorbidity score, mean (95% CI) 7.6 (7.4–7.7) 7.4 (7.1–7.7) 7.7 (7.4–8.1) 7.6 (6.9–8.3) 6.9 (6.5–7.4) 8.0 (7.3–8.6) 7.6 (7.4–7.8) 0.166
≥ 1 Radiation claim, n (%) 251 (45.2) 37 (29.8) 44 (61.1) 18 (47.4) 9 (29.0) 14 (48.3) 129 (49.4) < 0.001
≥ 1 Surgery claim, n (%) 397 (71.5) 96 (77.4) 53 (73.6) 28 (73.7) 20 (64.5) 20 (69.0) 180 (69.0) 0.544
Length of follow-up (days), mean (95% CI) 325.8 (303.6–347.9) 363.6 (313.9–413.3) 316.0 (261.8–370.2) 317.8 (234.6–401.0) 365.4 (254.9–475.8) 186.1 (121.3–251.0) 322.4 (289.6–355.3) 0.043
  1. DOC docetaxel, DOX doxorubicin, GEM gemcitabine, IFO ifosfamide, PAZO pazopanib, SD standard deviation